COVID-19 /

Vaccine Variables - What Are All The Moving Parts Behind The Push?

Are we starting to see a pattern here?


Photo for: Vaccine Variables - What Are All The Moving Parts Behind The Push?

Key Points

  • Over 315M COVID vaccines have been administered in the US
  • 148M people in the US have been fully vaccinated

As we explore the connections between big pharma, big government and COVID-19, as we discussed in our last few podcasts here on the Drill Down, we have to look at some current updates. Despite being vaccinated many people, all across the world, are still becoming infected with the COVID-19 virus. Why is it that many are falling ill once they are vaccinated and still contracting the very virus the “vaccine” is supposed to stop. In Indonesia, hundreds of medical workers are struggling to make sense of why the vaccination isn’t doing more:

More than 350 doctors and medical workers have caught COVID-19 in Indonesia despite being vaccinated with Sinovac and dozens have been hospitalized, officials said, as concerns grow about the efficacy of some vaccines against more infectious variants.

Most of the workers were asymptomatic and self-isolating at home, said Badai Ismoyo, head of the health office in the district of Kudus in central Java, but dozens were in hospital with high fevers and declining oxygen saturation levels.

We have to also ask the question of why more patients with COVID-19 are not following the early treatment protocols, which have been proven to work, such as Hydroxychloroquine. Not to mention the overwhelming statistical support that those who have had the virus do not need to also be vaccinated. So why the push?

If we look at the cost of Hydroxychloroquine, there was no money to be made with this early, inexpensive treatment, and that applied to ivermectin as well. When we look at the deals recently with pharmaceutical companies and the United States, we have to start to question motives. Why are the deals between Merck and the FDA important to the American public…because it’s worth 1.2 billion dollars. Why was a paid Gilead doctor, Mandeep R Mehra, on a panel about Remdivisir, where he never disclosed his interests in the company ahead of the article he wrote for the Lancet?

We’re starting to see a pattern here.